LPGO — Lipigon Pharmaceuticals AB Income Statement
0.000.00%
Last trade - 00:00- SEK16.24m
- SEK4.47m
- SEK20.57m
Annual income statement for Lipigon Pharmaceuticals AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 8.02 | 4.42 | 0 | 32.8 | 20.6 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 24.2 | 86.8 | 75.5 | 57.6 | 71.7 |
| Operating Profit | -16.1 | -82.4 | -75.5 | -24.7 | -51.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -16.1 | -82.2 | -75.4 | -24.3 | -50.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -16.1 | -82.2 | -75.4 | -24.3 | -50.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.1 | -82.2 | -75.4 | -24.3 | -50.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.1 | -82.2 | -75.4 | -24.3 | -50.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.18 | -7.54 | -4.24 | -0.378 | -0.365 |
| Dividends per Share |